Recently, considering the benefits of combinatorial treatments of anti-PD-1 and anti-CTLA-4 monoclonal antibodies, such as nivolumab and ipilimumab, in many types of cancer [23,24] a small pilot study was carried out also on TNBC, highlighting a positive response in 16.7% of patients when they were treated with the anti-PD-L1 durvalumab and the anti-CTLA-4 mAb tremelimumab [25]. Here, CD274 is linked to cancer.